[{"arm_notes": "nan", "treatment_id": null, "treatment_name": "Moderna", "treatment_type": "Biological", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": null, "treatment_name": "Moderna;Pfizer", "treatment_type": "Biological;Biological", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": null, "treatment_name": "Moderna;Pfizer", "treatment_type": "Biological;Biological", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "nan", "treatment_id": null, "treatment_name": "Pfizer", "treatment_type": "Biological", "pharmacological_treatment": "Non pharmacological treatment"}]

[{"arm_notes": "Homologous prime/boost;For whom a 2nd dose of mRNA vaccine is planned within 4 to 6 weeks (according to the recommendations of the HAS and the ANSM).", "treatment_id": 824, "treatment_name": "Mrna-1273", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Heterologous Moderna-Pfizer;For whom a 2nd dose of mRNA vaccine is planned within 4 to 6 weeks (according to the recommendations of the HAS and the ANSM).", "treatment_id": 1431, "treatment_name": "Bnt162b2+mrna-1273", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Homologous prime/boost;For whom a 2nd dose of mRNA vaccine is planned within 4 to 6 weeks (according to the recommendations of the HAS and the ANSM).", "treatment_id": 222, "treatment_name": "Bnt162b2", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}, {"arm_notes": "Heterologous Pfizer-Moderna;For whom a 2nd dose of mRNA vaccine is planned within 4 to 6 weeks (according to the recommendations of the HAS and the ANSM).", "treatment_id": 1431, "treatment_name": "Bnt162b2+mrna-1273", "treatment_type": "Rna based vaccine", "pharmacological_treatment": "Vaccine"}]